Log In
Print this Print this

morphine/oxycodone (MoxDuo IR) (Q8003 IR)

  Manage Alerts
Collapse Summary General Information
Company QRxPharma Ltd.
DescriptionImmediate-release combination of oxycodone and morphine
Molecular Target Mu opioid receptor (MOR) (OPRM1)
Mechanism of ActionMu opioid receptor agonist
Therapeutic ModalitySmall molecule: Combination
Latest Stage of DevelopmentRegistration
Standard IndicationPain
Indication DetailsTreat moderate to severe acute pain; Treat moderate to severe pain following bunionectomy; Treat moderate to severe post-operative pain following total knee replacement surgery
Regulatory Designation U.S. - Undisclosed Review (Treat moderate to severe acute pain)
PartnerAllergan plc;
Aspen Pharmacare Holdings Ltd.;
Endo International plc;
Teva Pharmaceutical Industries Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments





 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today